Theravance Biopharma, Inc. 8-K

What Happened

• On May 7, 2026, Theravance Biopharma, Inc. announced its financial results for the quarter ended March 31, 2026, and provided a business update via a press release. The release was furnished as Exhibit 99.1 to the company's Current Report on Form 8-K (Item 2.02).

Key Details

• Date of 8-K and press release: May 7, 2026.
• Reporting period: quarter ended March 31, 2026.
• The press release is furnished as Exhibit 99.1 to the 8-K.
• The furnished press release is expressly stated as not being “filed” for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into other filings, per Item 9.01.

Why It Matters

• This 8-K signals that Theravance has released its latest quarterly earnings and operational update—information investors use to assess recent revenue, expenses, cash position, and business progress.
• Because the press release is furnished (not “filed”), it is available to investors but carries different legal liability and incorporation implications than a filed disclosure.
• Investors should review the Exhibit 99.1 press release (on EDGAR or the company’s investor relations site) for the specific financial figures, guidance, and operational details that could affect valuation or near-term trading decisions.